Literature DB >> 29177557

Can checkpoint inhibitor therapy improve response to chemotherapy?

Michael Constantin Kirchberger1, Bastian Schilling2,3, Sebastian Haferkamp4, Anja Bosserhoff5, Gerold Schuler1, Lucie Heinzerling6.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29177557     DOI： 10.1007/s00432-017-2546-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  8 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.

Authors:  Michael C Kirchberger; Axel Hauschild; Gerold Schuler; Lucie Heinzerling
Journal:  Eur J Cancer       Date:  2016-08-06       Impact factor: 9.162

3.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

4.  Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Authors:  Antoni Ribas; Richard Kefford; Margaret A Marshall; Cornelis J A Punt; John B Haanen; Maribel Marmol; Claus Garbe; Helen Gogas; Jacob Schachter; Gerald Linette; Paul Lorigan; Kari L Kendra; Michele Maio; Uwe Trefzer; Michael Smylie; Grant A McArthur; Brigitte Dreno; Paul D Nathan; Jacek Mackiewicz; John M Kirkwood; Jesus Gomez-Navarro; Bo Huang; Dmitri Pavlov; Axel Hauschild
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

5.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

Authors:  Christina Pfirschke; Camilla Engblom; Steffen Rickelt; Virna Cortez-Retamozo; Christopher Garris; Ferdinando Pucci; Takahiro Yamazaki; Vichnou Poirier-Colame; Andita Newton; Younes Redouane; Yi-Jang Lin; Gregory Wojtkiewicz; Yoshiko Iwamoto; Mari Mino-Kenudson; Tiffany G Huynh; Richard O Hynes; Gordon J Freeman; Guido Kroemer; Laurence Zitvogel; Ralph Weissleder; Mikael J Pittet
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

6.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

7.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

8.  Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.

Authors:  Annette Pflugfelder; Thomas K Eigentler; Ulrike Keim; Benjamin Weide; Ulrike Leiter; Kristian Ikenberg; Mark Berneburg; Claus Garbe
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.